AUS
NZ
UK
CA
USA
IND
Highlights
Prescient Therapeutics extends Share Purchase Plan deadline
Funds allocated to advance Phase 2 trial for oncology candidate PTX-100
Broader pipeline includes cell therapy enhancements and modular CAR-T platform
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), a biotechnology company listed on the ASX 300, has revised the timeline of its current Share Purchase Plan. The extension is aimed at providing eligible shareholders more time to participate in the offer. The company seeks to raise funds to support the Phase 2 development of its lead oncology candidate, PTX-100.
The extended plan now sets a new deadline for participation and a revised timeline for share issuance and trading commencement. This adjustment follows initial interest and ongoing engagement with shareholders.
Use of Proceeds to Support PTX-100 Clinical Milestones
Capital raised through the Share Purchase Plan will be used primarily to support clinical activities associated with PTX-100, Prescient’s lead therapeutic compound. PTX-100 is described as a first-in-class inhibitor targeting geranylgeranyl transferase-1 (GGT-1), which has shown a positive safety profile in early-stage trials.
A Phase 2a study focused on cutaneous T-cell lymphoma (CTCL) is ongoing, and the trial aims to enrol a group of patients under clinical assessment. PTX-100 has secured both Orphan Drug and Fast Track Designations from the United States Food and Drug Administration, reflecting its focus on rare and aggressive cancer types.
Pipeline Innovation Includes Modular Cell Therapy Enhancements
Prescient's broader clinical pipeline includes advanced cell therapy platforms designed to improve current approaches in oncology. These platforms feature manufacturing enhancements and adaptive delivery strategies across both solid and haematological malignancies.
CellPryme-M, a manufacturing-stage enhancement tool, aims to improve tumour targeting and persistence in adoptive cell therapies. CellPryme-A is designed as an immune-supportive adjuvant to enhance overall treatment effectiveness by mitigating tumour-induced suppression.
OmniCAR, another key asset in Prescient’s portfolio, serves as a modular CAR-T platform. It enables on-demand and precise multi-antigen targeting, offering flexibility and control in treatment regimens.
Shareholder Engagement via Upcoming CEO Briefing
Prescient Therapeutics will host a live shareholder briefing to outline the details of the Share Purchase Plan, intended use of proceeds, and the development path for PTX-100. The event offers stakeholders an opportunity to engage directly with company leadership on strategic direction and ongoing programs.
The briefing will be conducted by Prescient's CEO and is scheduled to take place ahead of the new plan deadline. It marks an important touchpoint in the company’s broader communication strategy as it continues to progress in the clinical oncology space.
